Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

BACKGROUND: The epidermal growth factor receptor (EGFR) is an established target for anti-cancer treatment in different tumour types. Two different strategies have been explored to inhibit this pivotal molecule in epithelial cancer development: small molecules TKIs and monoclonal antibodies. ErbB/HE...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cavazzoni, Andrea, Alfieri, Roberta R, Cretella, Daniele, Saccani, Francesca, Ampollini, Luca, Galetti, Maricla, Quaini, Federico, Graiani, Gallia, Madeddu, Denise, Mozzoni, Paola, Galvani, Elena, La Monica, Silvia, Bonelli, Mara, Fumarola, Claudia, Mutti, Antonio, Carbognani, Paolo, Tiseo, Marcello, Barocelli, Elisabetta, Petronini, Pier Giorgio, Ardizzoni, Andrea
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3577499/
https://ncbi.nlm.nih.gov/pubmed/23234355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-91
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars